Stock Events

Stock Events

Korro Bio 

$12.65
58
+$1.33+11.75% Wednesday 20:00

Statistics

Day High
12.7
Day Low
11.43
52W High
55.89
52W Low
5.2
Volume
277,111
Avg. Volume
241,111
Mkt Cap
119.13M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-5.33
-4.13
-2.93
-1.73
Expected EPS
-1.726667
Actual EPS
N/A

Financials

-3,680.36%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
4.54MRevenue
-167.16MNet Income

Analyst Ratings

$19.75Average Price Target
The highest estimate is 30.00.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy
80%
Hold
20%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KRRO. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Beam Therapeutics
BEAM
Mkt Cap2.53B
Beam Therapeutics uses base editing technology, similar to Korro Bio's RNA editing, for precise genetic modifications.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine is involved in genome editing using CRISPR technology, competing in the broader genetic modification space.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is a leader in CRISPR-Cas9 technology for gene editing, directly competing in the genetic therapy market.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics focuses on CRISPR-Cas9 for gene editing, similar to Korro Bio's focus on precise genetic modifications.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics works on genome editing and gene therapy, including zinc finger nuclease technology, competing in gene modification.
Precision Biosciences
DTIL
Mkt Cap96.18M
Precision BioSciences utilizes its ARCUS genome editing platform, offering a different approach but competing in the same space as Korro Bio.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, which, while a different technology, competes in the RNA-based therapy market.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, competing in the RNA therapy space.
Novartis
NVS
Mkt Cap237.61B
Novartis has a broad portfolio including gene therapies and investments in genetic editing technologies, making it a competitor on multiple fronts.

About

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
Show more...
CEO
Dr. Ram Aiyar MBA, Ph.D.
Employees
112
Country
US
ISIN
US5009461089

Listings

BOATS
BOATS
KRRO.BOATS
XNAS
US
KRRO

0 Comments

Share your thoughts

FAQ

What is Korro Bio stock price today?▼
The current price of KRRO is $12.65 USD — it has increased by +11.75% in the past 24 hours. Watch Korro Bio stock price performance more closely on the chart.
What is Korro Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Korro Bio stocks are traded under the ticker KRRO.
Is Korro Bio stock price growing?▼
KRRO stock has risen by +15.95% compared to the previous week, the month change is a +10% rise, over the last year Korro Bio has showed a -27.05% decrease.
What is Korro Bio market cap?▼
Today Korro Bio has the market capitalization of 119.13M
When is the next Korro Bio earnings date?▼
Korro Bio is going to release the next earnings report on May 19, 2026.
What were Korro Bio earnings last quarter?▼
KRRO earnings for the last quarter are -5.33 USD per share, whereas the estimation was -2.07 USD resulting in a -157.45% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Korro Bio revenue for the last year?▼
Korro Bio revenue for the last year amounts to 4.54M USD.
What is Korro Bio net income for the last year?▼
KRRO net income for the last year is -167.16M USD.
How many employees does Korro Bio have?▼
As of April 02, 2026, the company has 112 employees.
In which sector is Korro Bio located?▼
Korro Bio operates in the Health Care sector.
When did Korro Bio complete a stock split?▼
The last stock split for Korro Bio was on November 06, 2023 with a ratio of 1:50.
Where is Korro Bio headquartered?▼
Korro Bio is headquartered in Cambridge, US.